AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02237365
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg placebo (visually matched to 500mg aspirin) daily for 60 days
Trial: NCT04332107
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will be shipped a single 1.2 g dose of oral azithromycin
Trial: NCT04332107
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be shipped a dose of matching placebo
Trial: NCT02052752
Drug: Neutrogena Rapid Clear®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A commercial product containing 2% salicylic acid that reportedly improves acne lesions was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
Trial: NCT02348593
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01223690
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
Trial: NCT01223690
Drug: Dextrose 5%
RxNorm normalized name: Dextrose 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
Trial: NCT00479713
Drug: ezetimibe (+) simvastatin
RxNorm normalized name: ezetimibe / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe/simvastatin 10/20mg. The treatment duration will be 6 weeks.
Trial: NCT00479713
Drug: Comparator : rosuvastatin calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 10mg. The treatment duration will be 6 weeks.
Trial: NCT00479713
Drug: Comparator: Placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 10mg Placebo. The treatment duration will be 6 weeks.
Trial: NCT00479713
Drug: Comparator: Placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe/simvastatin 10/20mg Placebo. The treatment duration will be 6 weeks.
Trial: NCT00149890
Drug: Steroid
RxNorm normalized name: Steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous prednisolone (loading dose: 300 mg/m2, maximum 500 mg) had to be administered intraoperatively only in treatment arm 1 (day 0). The first dose of steroids in treatment arm 2 (day 0) had to be administered within 8 hours after reperfusion of the graft. Beginning from day 1 to day 6 doses of 15 mg/m2/day had to be given intravenously (i.v.) in both treatment arms. Then, the steroid doses (oral prednisone or its equivalent) were to be decreased from 10 mg/m²/day orally (day 7-13), to 7.5 mg/m²/day orally (day 14-30), to 4 mg/m²/day orally (until end of month 2), to 2.5 mg/m²/day orally (until end of month 3) and to 1 mg/m²/day orally (until end of month 6).
Trial: NCT00853866
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, 80 min before assessment of Jebsen Taylor test
Trial: NCT04503265
Drug: AMXI-5001:Dose Escalation Phase I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I will enroll up to 70 participants to identify the Recommended Phase II daily dose in the treatment of various cancers and to characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
Trial: NCT04503265
Drug: AMXI-5001:Dose Expansion Phase II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase II will enroll up to 52 study participants to further characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
Trial: NCT04135378
Drug: ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study Group :- ascorbic acid ( 500 mg per day) for one week before presentation
Trial: NCT01152190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, once daily for 8 weeks
Trial: NCT01595321
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (Cy) 200 mg/m\^2 administered one day prior to GVAX (day 0). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional CY/GVAX boosts may be given every 6 months thereafter until disease recurrence.
Trial: NCT01595321
Drug: FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRINOX is given over six 28-day cycles, starting at least 1 weeks after SBRT.~FOLFIRINOX consists of the following drugs given IV on days 1 and 15 of each cycle:~Oxaliplatin (85 mg/m\^2), Irinotecan (180 mg/m\^2), Leucovorin (400 mg/m\^2), Fluorouracil (400 mg/m\^2 bolus followed by 2,400 mg/m\^2 continuous infusion over 46-48 hours);~modified FOLFIRINOX consists of the same regimen described above but without the 400 mg/m\^2 Fluorouracil bolus.
Trial: NCT00834834
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose of 20 mg daily will increase over 4 weeks, depending on tolerability, up to 40 mg daily. Treatment will last 6 months.
Trial: NCT00687388
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mg daily for 8 weeks
Trial: NCT00687388
Drug: alpha-blocker and NSAID
RxNorm normalized name: ALPHA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks and celecoxib 200mg daily for 8 weeks
Trial: NCT02801071
Drug: 15g L-citrulline daily p.o.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02801071
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03140657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to Placebo Arm will receive placebo in the form of capsules for 4 months
Trial: NCT00092755
Drug: MK0663, etoricoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00092755
Drug: Comparators: ibuprofen and placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01291563
Drug: TMC207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 tablets of TMC207 (100 mg/tablet) on Day 1
Trial: NCT01291563
Drug: TMC207 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 tablets of TMC207 placebo on Day 1
Trial: NCT02315833
Drug: Acetium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule for oral administration contains L-cysteine 100mg
Trial: NCT02315833
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo capsule matching Acetium for oral administration.
Trial: NCT03824457
Drug: Rheosorbilact®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
Trial: NCT03824457
Drug: Ringer lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
Trial: NCT03512756
Drug: Capecitabine, Gemcitabine, and 5-FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator choice of the following therapies:~Capecitabine, Gemcitabine, and 5-FU
Trial: NCT01348880
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of placebo to match 10 mg vardenafil ODT. taken without water
Trial: NCT03860844
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Trial: NCT03860844
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Trial: NCT03860844
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
Trial: NCT02845999
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: day -6 : cyclophosphamide 60 mg/Kg
Trial: NCT00411099
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01209039
Drug: GSK1144814
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily doses of GSK1144814 for 14 days
Trial: NCT01209039
Drug: GSK1144814
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily doses of GSK1144814 for 7 days (or until steady state is reached)
Trial: NCT03463135
Drug: Placebo for GLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual
Trial: NCT02517697
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral formulation of matching placebo three times daily for 12 weeks
Trial: NCT02001935
Drug: theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After oral theophylline 200mg per day for two weeks,bood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2 and CYP2E1
Trial: NCT04656886
Drug: Intravenous Infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00284700
Drug: Iron
RxNorm normalized name: Iron
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04487236
Drug: ZN-A-1041 50mg BID
RxNorm normalized name: zinc acetate 50 MG
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Orally 21days for one cycle
Trial: NCT04487236
Drug: ZN-A-1041 100mg BID
RxNorm normalized name: dimethicone 10 MG/ML / zinc oxide 100 MG/ML [A+D Diaper Rash]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally 21days for one cycle
Trial: NCT04487236
Drug: ZN-A-1041 200mg BID
RxNorm normalized name: zinc undecylenate 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally 21days for one cycle
Trial: NCT04487236
Drug: ZN-A-1041 400mg BID
RxNorm normalized name: zinc oxide 400 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally 21days for one cycle
Trial: NCT04487236
Drug: ZN-A-1041 600mg BID
RxNorm normalized name: VITAMIN A/VITAMIN D/ZINC OXIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally 21days for one cycle
Trial: NCT04487236
Drug: ZN-A-1041 800mg BID
RxNorm normalized name: VITAMIN A/VITAMIN D/ZINC OXIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally 21days for one cycle
Trial: NCT04487236
Drug: ZN-A-1041 1000mg BID
RxNorm normalized name: zinc-DTPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally 21days for one cycle
Trial: NCT00396851
Drug: Gurmar
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01310465
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: zoledronic acid, 5mg(100ml), intravenous, one time at three days postoperatively
Trial: NCT00129948
Drug: Troxatyl™ (troxacitabine)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00616733
Drug: CS-0777 tablets
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg, once-weekly, for 12 weeks
Trial: NCT00616733
Drug: CS-0777 tablets
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg, once-weekly or once every 2 weeks, for 12 weeks
Trial: NCT00771199
Drug: Transdermal Therapeutic System (TTS)-Fentanyl
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1 transdermal patch of TTS-fentanyl containing 12 micrograms per hour (mcg/h) for 28 days. Dose can be increased or decreased as per Investigator's discretion up to 100 mcg/h.
Trial: NCT00649506
Drug: Macrodantin® 100 mg Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg, single dose fed
Trial: NCT03777059
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching atogepant tablets
Trial: NCT01984086
Drug: Salbutamol Sulphate 150mcg UD-DPI Blister(1.6% blend)
RxNorm normalized name: Blister Armour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol Sulphate 150mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
Trial: NCT01984086
Drug: Salbutamol Sulphate UD-DPI Blister (selected from Part A)
RxNorm normalized name: Blister Armour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation will be determined depending on the outcome of Part A.
Trial: NCT02171104
Drug: IMD Preparative Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan
Trial: NCT02171104
Drug: Osteopetrosis Only Preparative Regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan~* Thiotepa
Trial: NCT02171104
Drug: Osteopetrosis Haploidentical Only Preparative Regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Rituximab~* Alemtuzumab~* Busulfan~* Fludarabine
Trial: NCT02171104
Drug: cALD SR-A (Standard-Risk, Regimen A)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine start day +1 through day +28
Trial: NCT02171104
Drug: cALD SR-B (Standard-Risk, Regimen B)
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine start day +1through day +56
Trial: NCT02171104
Drug: cALD HR-D (High-Risk, Regimen C)
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine and celecoxib start day of admission (prior to conditioning regimen) and continue through day +100
Trial: NCT02171104
Drug: cALD HR-D (High-Risk, Regimen D)
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine, celecoxib, vitamin E and alpha lipoic acid start day of admission (prior to conditioning regimen) and continue through day +100
Trial: NCT02899000
Drug: Oral doxycycline hyclate
RxNorm normalized name: Doxycycline Hyclate
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline-class oral antibacterial 200 mg daily (2 tablets \[50 mg\], twice daily)
Trial: NCT01307046
Drug: MK-0954A
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
Trial: NCT02832544
Drug: Vitamin K antagonists (VKA)
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02041325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.
Trial: NCT04367831
Drug: Heparin Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin infusion at 10 units/kg/hour with goal anti-Xa 0.1 -0.3U/mL.
Trial: NCT04367831
Drug: Heparin SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin at 5000-7500 units subcutaneous (SC) every 8 hours.
Trial: NCT03789916
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg die
Trial: NCT02448797
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 25 mg/m\^2, intravenously guttae, day 1 and day 8, 21 days/cycle, 4 cycles, cisplatin 75 mg/m\^2, intravenously guttae, day 1, 21 days/cycle, 4 cycles. For adenocarcinoma: pemetrexed (500 mg/m\^2, day 1)/cisplatin (75 mg/m\^2, day 1) for 4 cycles.
Trial: NCT02263508
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intratumoral injection
Trial: NCT03373149
Drug: Growth hormone/HPuFSH/GnRH antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (Somatropin, Sedico, Egypt) \[4 IU/day\] and highly purified urinary FSH (HPuFSH) (Fostimon,IBSA, Switzerland) \[300 IU/day\] will be started on cycle day 3 and will be continued until and including the day of human chorionic gonadotropin (HCG) administration. Starting from cycle day 8, the dose of HPuFSH will be adjusted individually according to ovarian response which will be monitored using transvaginal ultrasound and serum estradiol (E2).~GnRH antagonist (Cetrorelix acetate) (Cetrotide; Serono International S.A., Geneva, Switzerland) 0.25 mg S.C. once daily will be started when the leading follicle is 14 mm in mean diameter and will be continued until and including the day of HCG administration.
Trial: NCT02108106
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01266265
Drug: inhaled prostacyclin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyvaso
Trial: NCT03373149
Drug: HPuFSH/GnRH antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly purified urinary FSH (HPuFSH) (Fostimon,IBSA, Switzerland) \[300 IU/day\] will be started on cycle day 3 and will be continued until and including the day of human chorionic gonadotropin (HCG) administration. Starting from cycle day 8, the dose of HPuFSH will be adjusted individually according to ovarian response which will be monitored using transvaginal ultrasound and serum estradiol (E2).~GnRH antagonist (Cetrorelix acetate) (Cetrotide; Serono International S.A., Geneva, Switzerland) 0.25 mg S.C. once daily will be started when the leading follicle is 14 mm in mean diameter and will be continued until and including the day of HCG administration.
Trial: NCT00825188
Drug: eplerenone, amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone 25mm qd versus amlodipine 5mg qd x 4weeks the Eplerenone 50mg qd versus amlodipine 10mg qd x 4weeks
Trial: NCT00825188
Drug: eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eplerenone 25-50mg daily x 8 weeks
Trial: NCT00825188
Drug: eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: eplerenone 25- 50 mg daily for 8 weeks
Trial: NCT01266265
Drug: oral ERA
RxNorm normalized name: ALCOHOL 4 mL TOPICAL CLOTH [Bioserica ERA Alcohol Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed by physician
Trial: NCT00210782
Drug: topiramate, phenytoin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01796782
Drug: QYHJ Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-4 bags bid , days 1-42, every 6 weeks
Trial: NCT01191892
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of vandetanib tablet
Trial: NCT02477670
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03546907
Drug: SAR440340
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection; Route of administration: SC
Trial: NCT03546907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection; Route of administration: SC
Trial: NCT03546907
Drug: Any Inhaled Corticosteroids as prescribed by treating physician as standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Aerosol or Dry Powder inhaler Route of administration: Inhaled
Trial: NCT00228007
Drug: Antidepressant Medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02139046
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen tablets
Trial: NCT01779232
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered daily like the active comparator
Trial: NCT00381004
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Course 1: 250 mg/m\^2 by vein over 5-30 minutes on Days 2, 3, and 4; Course 2 - 6: 250 mg/m\^2 by vein over 5-30 minutes on Days 1 - 3
Trial: NCT02965248
Drug: Standard adjuvant systemic chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients undergo radical surgery with standard adjuvant systemic chemotherapy (mFOLFOX6/CapeOx/sLV5FU2/Cape).~mFOLFOX6: oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~CapeOx: oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.~sLV5FU2: leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~Cape: capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.
Trial: NCT00062179
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib: 400 mg po BID celecoxib 3-7 days before first dose of chemotherapy